FTC Accuses Endo Pharmaceuticals Of "Pay-For-Delay" Agreements; Analysts Not Worried
The Federal Trade Commission said Thursday that Endo Pharmaceuticals violated federal antitrust laws by paying Impax Laboratories and Watson Laboratories to delay launching their approved generic versions. The latest case is the first by the commission that challenges an agreement not to market an authorized generic.
SORRY! This content is exclusively for paying members. If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.
FTC claims "pay-for-delay" agreements cost consumers billions
